Patents by Inventor David B. Belanger

David B. Belanger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 9957254
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: May 1, 2018
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Philippe Bolduc, Takeru Ehara, Luciana Ferrara, Nan Ji, Mitsunori Kato, Erik Meredith, Muneto Mogi, James J. Powers, Ganesh Prasanna
  • Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
    Patent number: 9765067
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 19, 2017
    Assignee: Novartis AG
    Inventors: Christopher M. Adams, David B. Belanger, Doug Bevan, Takeru Ehara, Luciana Ferrara, Nan Ji, Donglei Liu, Erik Meredith, Muneto Mogi, James Powers, Ganesh Prasanna, Mitsunori Kato
  • THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197950
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Takeru EHARA, Luciana FERRARA, Nan JI, Donglei LIU, Erik MEREDITH, Muneto MOGI, James POWERS, Ganesh PRASANNA, Mitsunori KATO
  • CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20170197941
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 13, 2017
    Applicant: NOVARTIS AG
    Inventors: Christopher M. ADAMS, David B. BELANGER, Doug BEVAN, Philippe BOLDUC, Takeru EHARA, Luciana FERRARA, Nan JI, Mitsunori KATO, Erik MEREDITH, Muneto MOGI, James J. POWERS, Ganesh PRASANNA
  • Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof
    Publication number: 20160145247
    Abstract: The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 26, 2016
    Applicant: NOVARTIS AG
    Inventors: David B. BELANGER, Stefanie FLOHR, Christine Fang GELIN, Keith JENDZA, Nan JI, Donglei LIU, Edwige Lilliane Jeanne LORTHIOIS, Rakeshri Ganesh KARKI, Nello MAINOLFI, James J. POWERS, Stefan Andreas RANDL, Olivier ROGEL, Anna VULPETTI, Taeyoung YOON
  • Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
    Patent number: 9227971
    Abstract: The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: January 5, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: M. Arshad Siddiqui, Yang Nan, Mehul F. Patel, Panduranga Adulla P. Reddy, Umar Faruk Mansoor, Zhaoyang Meng, Lalanthi Dilrukshi Vitharana, Lianyun Zhao, Amit K. Mandal, Duan Liu, Shuyi Tang, Andrew McRiner, David B. Belanger, Patrick J. Curran, Chaoyang Dai, Angie R. Angeles, Liping Yang, Matthew Hersh Daniels
  • PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
    Publication number: 20120322791
    Abstract: The present invention provides Pyrazolopyrimidine Compounds of Formula (I): wherein L, T, Z, U, V, W, R3, R6, R7, R8, and m are as defined herein, and pharmaceutically acceptable salts of such Pyrazolopyrimidine Compounds. The Pyrazolopyrimidine Compounds are useful in the treatment of cancer and other diseases or disorders wherein mTOR is deregulated.
    Type: Application
    Filed: January 18, 2011
    Publication date: December 20, 2012
    Inventors: M. Arshad Siddiqui, Yang Nan, Mehul F. Patel, Panduranga Adulla P. Reddy, Umar Faruk Mansoor, Zhaoyang Meng, Lalanthi Dilrukshi Vitharana, Lianyun Zhao, Amit K. Mandal, Duan Liu, Shuyi Tang, Andrew McRiner, David B. Belanger, Patrick J. Curran, Chaoyang Dai, Angie R. Angeles, Liping Yang, Matthew Hersh Daniels
  • Substituted pyridines that are JNK inhibitors
    Patent number: 8278337
    Abstract: Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: October 2, 2012
    Assignee: Merck Sharp & Dohme
    Inventors: David B. Belanger, M. Arshad Siddiqui, Patrick J. Curran, Blake Hamann, Lianyun Zhao, Panduranga Adulla P. Reddy, Praveen K. Tadikonda, Gerald W. Shipps, Jr., Umar Faruk Mansoor
  • NOVEL JNK INHIBITORS
    Publication number: 20100298314
    Abstract: Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.
    Type: Application
    Filed: December 17, 2007
    Publication date: November 25, 2010
    Inventors: Panduranga Adulla P. Reddy, M. Arshad Siddiqui, Praveen K. Tadikonda, Umar Faruk Mansoor, Gerald W. Shipps, JR., David B. Belanger, Lianyun Zhao
  • NOVEL JNK INHIBITORS
    Publication number: 20100179141
    Abstract: Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.
    Type: Application
    Filed: December 17, 2007
    Publication date: July 15, 2010
    Inventors: David B. Belanger, M. Arshad Siddiqui, Patrick J. Curran, Blake Hamann, Lianyun Zhao, Panduranga Adulla P. Reddy, Praveen K. Tadikonda, Gerald W. Shipps, JR., Umar Faruk Mansoor
  • COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20100145048
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Application
    Filed: October 20, 2009
    Publication date: June 10, 2010
    Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert D. Mazzola, Tin-Yau Chan, Henry A. Vaccaro, Brian McKittrick, Joseph A. Kozlowski, Brian J. Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline C. Ting, Kristin E. Rosner, Gerald W. Shipps, JR., M. Arshad Siddiqui, David B. Belanger, Chaoyang Dai, Dansu Li, Vinay M. Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7652020
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-? or combinations thereof.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: January 26, 2010
    Assignee: Schering Corporation
    Inventors: Zhuyan Guo, Peter Orth, Zhaoning Zhu, Robert D. Mazzola, Tin-Yau Chan, Henry A. Vaccaro, Brian McKittrick, Joseph A. Kozlowski, Brian J. Lavey, Guowei Zhou, Sunil Paliwal, Shing-Chun Wong, Neng-Yang Shih, Pauline C. Ting, Kristin E. Rosner, Gerald W. Shipps, Jr., M. Arshad Siddiqui, David B. Belanger, Chaoyang Dai, Dansu Li, Vinay M. Girijavallabhan, Janeta Popovici-Muller, Wensheng Yu, Lianyun Zhao
  • Imidazopyrazines as cyclin dependent kinase inhibitors
    Patent number: 7576085
    Abstract: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: August 18, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Lianyun Zhao, Patrick J. Curran, David B. Belanger, Blake Hamann, Panduranga A. Reddy, M. Arshad Siddiqui
  • Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
    Patent number: 7563798
    Abstract: In its many embodiments, the present invention provides a class of pyrazolo [1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: July 21, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, M. Arshad Siddiqui, Panduranga Adulla P. Reddy, David B. Belanger, Blake Hamann, Patrick J. Curran
  • Imidazopyrazines as protein kinase inhibitors
    Patent number: 7511040
    Abstract: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: March 31, 2009
    Assignee: Schering Corporation
    Inventors: David B. Belanger, M. Arshad Siddiqui, Timothy J. Guzi, Patrick J. Curran, Praveen K. Tadikonda, Blake Hamann, Panduranga Adulla P. Reddy, Lianyun Zhao
  • IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS
    Publication number: 20080139571
    Abstract: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2007
    Publication date: June 12, 2008
    Inventors: David B. Belanger, M. Arshad Siddiqui, Timothy J. Guzi, Patrick J. Curran, Praveen K. Tadikonda, Blake Hamann, Panduranga Adulla P. Reddy, Lianyun Zhao
  • Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
    Publication number: 20080119515
    Abstract: Inhibitors of kinases, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptom.
    Type: Application
    Filed: March 10, 2004
    Publication date: May 22, 2008
    Inventors: M Arshad Siddiqui, David B. Belanger, Chaoyang Dai, Lianyun Zhao
  • 11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
    Patent number: 7060728
    Abstract: 11,12-Oxidoarachidonic acid derivatives and methods of their use for treating dry eye are disclosed.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: June 13, 2006
    Assignee: Alcon, Inc.
    Inventors: David B. Belanger, Peter G. Klimko
  • 11,12-Oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
    Publication number: 20040157805
    Abstract: 11,12-Oxidoarachidonic acid derivatives and methods of their use for treating dry eye are disclosed.
    Type: Application
    Filed: February 6, 2004
    Publication date: August 12, 2004
    Inventors: David B. Belanger, Peter G. Klimko
  • 11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
    Patent number: 6750250
    Abstract: 11,12-Oxidoarachidonic acid derivatives and methods of their use for treating dry eye are disclosed.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: June 15, 2004
    Assignee: Alcon, Inc.
    Inventors: David B. Belanger, Peter G. Klimko